Spreading the costs and pain in Part D

The Trump administration’s proposed changes to Medicare Part D would shift costs from the federal government to patients, manufacturers and insurers, all of which are sure to lobby against it and derail it in Congress.

On March 11, the administration unveiled its FY20 budget proposal, and in doing so laid bare its attempt to use the budget process as a vehicle for implementing the elements of its drug pricing blueprint that require legislation...